Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 10/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779177 | 0.91 | PTGDR2 (0.84) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL2778251 | 0.89 | PTGDR2 (0.79) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL2776683 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL2778507 | 0.88 | PTGDR2 (0.79) | PTGDR2PTGDRCYP2C9TBXA2R | |
| SCHEMBL503112 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL2516080 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL2522367 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL16558832 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL16558828 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGDRCYP2C9TBXA2RCYP3A4 | |
| SCHEMBL9989271 | 0.83 | PTGDR2 (0.87) | PTGDR2PTGDRCYP2C9TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | claimed |
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010054113-A2 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885CYP2C9 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.